Several studies have indicated that certain misfolded amyloids composed of tau, β-amyloid or α-synuclein can be transferred from cell to cell, suggesting the contribution of mechanisms reminiscent of those by which infective prions spread through the brain. This process of a 'prion-like' spreading between cells is also relevant as a novel putative therapeutic target that could block the spreading of proteinaceous aggregates throughout the brain which may underlie the progressive nature of neurodegenerative diseases. The relevance of β-amyloid oligomers and cellular prion protein (PrP C ) binding has been a focus of interest in Alzheimer's disease (AD). At the molecular level, β-amyloid/PrP C interaction takes place in two differently charged clusters of PrP C . In addition to β-amyloid, participation of PrP C in α-synuclein binding and brain spreading also appears to be relevant in α-synucleopathies. This review summarizes current knowledge about PrP C as a putative receptor for amyloid proteins and the physiological consequences of these interactions.
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Introduction
Neurodegenerative diseases are characterised by the progressive degeneration of subsets of neurons accompanied by complex glial reactions in specific brain regions (Ferrer, 2017) . Most neurodegenerative diseases develop and progress in parallel with a characteristic intra-or extra-cellular accumulation of misfolded PS including i) tau-containing neurofibrillary tangles (NFT) and β-amyloid plaques in Alzheimer's disease (AD) ( Fig. 1 ) (Braak and Del Trecidi, 2015) , ii) Lewy bodies (LB) and Lewy neurites (LN) containing α-synuclein in Parkinson's disease (PD) (Braak and Del Tredici, 2009 ) and dementia with Lewy bodies (DLB) (Goedert et al., 2013) , and α-synuclein oligodendroglial and neuronal deposits in multiple system atrophy (MSA) (Goedert et al., 2013) (Fig. 2) , and iii) TDP-43-positive skein-like and other inclusions in amyotrophic lateral sclerosis (ALS) (Guerrero et al., 2016 Abbreviations: AA, amino acid; Aβo, oligomeric β-amyloid; Aβ, β-amyloid; AD, Alzheimer's disease; α7nAChR, α7 nicotinic acetylcholine receptor; ALS, amyotrophic lateral sclerosis; APLP1, amyloid beta precursor-like protein 1; APP, amyloid precursor protein; β-ARs, β-adrenergic receptors; BSE, bovine spongiform encephalopathy; CamKII, calmodulin-dependent protein kinase II; CC1, charged cluster 1 (23-28 aa) of the PrP 
